CX3CR1 Antibody [G13H18]

Catalog No.: F8794

    Application: Reactivity:

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    使用情報

    Dilution
    1:500-1:1000
    1:500
    Application
    WB, IF
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Human, Mouse, Rat
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    40 kDa 52 kDa
    *なぜ予測分子量と実際の分子量が異なるのか?
    下記の原因により、実際の分子量が予測と異なる:タンパク質の翻訳後修飾(リン酸化/糖鎖付加),スプライシングバリアント,イソフォーム,相対的な電荷,ポリマー。

    Datasheet & SDS

    生物学的記述

    Specificity
    CX3CR1 Antibody [G13H18] detects endogenous levels of total CX3CR1 protein.
    Clone
    G13H18
    Synonym(s)
    Beta chemokine receptor-like 1, C-X3-C CKR-1, CMK-BRL-1, CMK-BRL1, Cx3c, CX3C chemokine receptor 1, V28, CCRL1, CMKBRL1, CMKDR1, CX3CR1, GPR13, GPRV28, Rbs11, V28
    Background
    CX3CR1 is a seven‑transmembrane G protein–coupled chemokine receptor of the CX3C family that serves as the cognate receptor for fractalkine/CX3CL1 and is expressed on selected immune and parenchymal cell populations, including monocytes, macrophages, microglia, subsets of CD8⁺ T cells, NK cells, and smooth muscle cells. The receptor binds both membrane‑anchored and soluble CX3CL1, with the N‑terminal chemokine domain of CX3CL1 engaging the extracellular loops of CX3CR1, while the transmembrane helices and intracellular loops couple to heterotrimeric G proteins and downstream signaling modules typical of chemokine GPCRs. CX3CR1 activation by membrane‑bound CX3CL1 promotes firm adhesion of CX3CR1‑positive leukocytes to endothelial or epithelial cells under flow, integrating chemokine receptor signaling with integrin activation and cytoskeletal rearrangements to stabilize immune cell–tissue contacts at sites of inflammation or in steady‑state surveillance niches. Soluble CX3CL1 binding to CX3CR1 triggers chemotactic signaling through Gαi‑dependent pathways, leading to inhibition of adenylyl cyclase, activation of PI3K and small GTPases, and reorganization of the actin cytoskeleton that supports directed migration of monocytes, T cells, NK cells, and other CX3CR1‑expressing subsets toward fractalkine gradients. CX3CL1–CX3CR1 engagement also activates survival and activation pathways in CX3CR1⁺ cells, including PI3K–Akt and ERK cascades, and influences expression of cytokines, cytotoxic mediators, and adhesion molecules, linking this axis to cell retention, effector differentiation, and resistance to apoptosis in tissue‑resident and circulating immune populations. In the nervous system, CX3CR1 on microglia and neuron‑associated macrophages binds neuronal CX3CL1 and participates in neuron–glia communication that regulates microglial activation state, synaptic pruning, and inflammatory responses to injury or neurodegeneration. Across inflammatory and infectious contexts, the CX3CL1–CX3CR1 axis coordinates leukocyte recruitment, adhesion, and positioning within tissues and contributes to the balance between protective immunity and chronic inflammation in diseases such as atherosclerosis, autoimmune disorders, and chronic infections. CX3CR1 also appears on CX3CR1⁺ CD8⁺ T cells enriched for effector and memory‑like features, where CX3CL1 binding supports their tissue homing, retention in inflamed or tumor sites, and participation in antitumor cytotoxic responses, making CX3CR1 a marker of highly functional cytotoxic T‑cell subsets. Genetic variation or dysregulated expression of CX3CR1 associates with altered susceptibility or progression in cardiovascular, neuroinflammatory, and malignant diseases, consistent with its central role in controlling leukocyte trafficking, survival, and effector function through fractalkine‑dependent chemotactic and adhesive signaling.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください